Clinical trials: Chronic Sinusitis Without Nasal Polyps
Chronic Sinusitis, Nasal Polyposis
S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps
The RESOLVE II Study is a randomized, single-blind, parallel arm, concurrently controlled, multicenter study with 300 chronic sinusitis patients who had prior endoscopic sinus surgery but present with recurrent sinus obstruction.
- Trial name
- RESOLVE_II (NCT02291549)
- Testing
- S8 Sinus Implant, Mometasone furoate nasal spray
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- Intersect ENT
Chronic Sinusitis, Nasal Polyps
Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps
The RESOLVE Study is a randomized controlled trial with the S8 Sinus Implant in 100 chronic sinusitis patients with recurrent nasal polyps.
- Trial name
- RESOLVE (NCT01732536)
- Testing
- S8 Sinus Implant, Mometasone furoate nasal spray
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Intersect ENT
Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior
Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis
To assess the efficacy of intra-sinus installation of a poloxamer gel that releases antibiotics and corticosteroids topically after balloon sinuplasty in chronic sinusitis patients with or without polyps.
- Conditions
- Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior
- Trial name
- NCT03472144
- Testing
- gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- LifeBridge Health
Chronic Sinusitis With or Without Nasal Polyps
Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or…
- Trial name
- NCT01623323
- Testing
- Fluticasone Propionate
- Where
- 18 sites in United States
- Volunteers
- 705 people
- Sponsor
- Optinose US Inc.